Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

Inclusion Criteria:

To participate in the study, all the following inclusion criteria must be met:

• Patients aged 18 years or older

• Written informed consent obtained before participating in the study.

• Patient is willing and able to complete the assessments, including PROquestionnaires, as outlined in this study.

• Diagnosis of RMS per McDonald Criteria (2017) occurred prior to initiation ofOfatumumab.

• Treatment with Ofatumumab is in accordance with the Portuguese indication ofKesimpta® (i.e., treatment of adult patients with relapsing multiple sclerosis (RMS)with active disease defined by clinical or imaging features).

• Patients that have initiated Ofatumumab up to 12 M prior inclusion in the study ORPatients that are initiating Ofatumumab at the moment of study inclusion.

Exclusion Criteria:

To participate in the study, none of the following exclusion criteria must be met:

• Use of investigational drugs during the study, OR between Ofatumumab initiation andinclusion into the study, OR within 5 half-lives of investigational drug beforeOfatumumab initiation, OR until the expected pharmacodynamic effect has returned tobaseline, whichever is longer.

• Use of high efficacy therapy (including Ocrelizumab, Natalizumab, Mitoxantrone,Rituximab and Alemtuzumab) in both cohorts prior to the initiation of Ofatumumab.